ALLEROD, Denmark, Jan 30 (Reuters) - A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will ...
Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...
Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down ...
Novo Nordisk A/S (NYSE:NVO) is among the most profitable healthcare stocks to buy. On January 26, BMO Capital lifted the ...
(Bloomberg) -- A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly expansion in almost four years. Gross domestic product rose 2 ...
The Novo Nordisk Foundation has allocated up to 736m euros in funding to BioInnovation Institute (BII), a leading institute ...
COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the ...
With attention in biotech focused on the JPM Healthcare conference in the US, the Novo Nordisk Foundation (NNF) has flown the flag for Europe by allocating DKK 5.5 billion (around €736 million) in ...
Jan 20 (Reuters) - Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have ...
Shares in Denmark's global healthcare company, Novo Nordisk jumped sharply on Friday after the U.K.'s regulator signed off on ...
Novo Nordisk A/S gains in GLP-1 obesity pills with strong U.S. marketing. Click for this NVO stock update and a preview of ...
This could finally be the start of the drugmaker's comeback.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results